■抗肿瘤坏死因子药物(抗-TNFs)已成为克罗恩病(CD)的主要医学疗法之一。我们分析了大型在线社区中对英夫利昔单抗和阿达木单抗的看法,以更好地了解患者获得的信息。
■Reddit,一个庞大的在线社区,有几个炎症性肠病社区,最大的是/r/克罗恩病(RCD),拥有超过41,000名成员。为了更好地了解患者对生物制剂的看法,我们在rCD中搜索了与英夫利昔单抗相关的帖子,\"\"阿达木单抗,\"及其相关商号。前20个年度职位分别来自2011年至2015年和2011年至2017年。执行清单编码。代码每20个职位重新评估一次,产生了6种主要情绪。计算每种情绪的总代码和每个评论代码。每个类别的百分比是通过除以当年编码情绪的总数来计算的。使用Spearman相关系数评估每种情绪的比率趋势。
■分析了4486条评论,4684种情绪符合我们的标准。随着时间的推移,两种抗TNF的负面情绪均降低(英夫利昔单抗:rho=-0.90,P=.04,阿达木单抗:rho=-0.79,P=.04)。在我们的初步分析中,2012年至2017年,阿达木单抗注射相关职位增加(rho=0.83,P=0.04)。关于药物成本的积极情绪和情绪,失去功效,饮食保持稳定。对于英夫利昔单抗和阿达木单抗,评论量随着时间的推移显著增加(rho0.90;P=.04,rho0.89,P=.01)。
我们对大型在线社区的分析显示,随着时间的推移,CD患者对生物疗法的接受度越来越高。这些数据为塑造患者对抗TNF的认知的多方面框架提供了额外的见解。
UNASSIGNED: Anti-tumor necrosis factor agents (anti-TNFs) have become one of the primary medical therapies for Crohn\'s disease (CD). We analyzed perceptions of infliximab and adalimumab in a large online community to better understand the information patients receive.
UNASSIGNED: Reddit, a vast online community, has several inflammatory bowel disease communities, the largest being /r/CrohnsDisease (rCD), with over 41,000 members. To better understand patient perceptions of biologics, we searched rCD for posts related to \"infliximab,\" \"adalimumab,\" and their relevant trade names. The top 20 yearly posts were extracted from 2011 to 2015 and 2011 to 2017, respectively. Manifest coding was performed. Codes were reassessed every 20 posts, resulting in 6 main sentiments. Total codes and per-comment codes were calculated for each sentiment. Percentages for each category were calculated by dividing by the total number of coded sentiments that year. Trends in rates of each sentiment were assessed using Spearman\'s correlation coefficients.
UNASSIGNED: 4486 comments were analyzed, and 4684 sentiments met our criteria. Negative sentiments decreased for both anti-TNFs over time (infliximab: rho = -0.90, P = .04, adalimumab: rho = -0.79, P = .04). In our primary analysis, adalimumab injection-related posts increased from 2012 to 2017 (rho = 0.83, P = .04). Positive sentiments and sentiments regarding drug costs, loss of efficacy, and diet remained stable. For infliximab and adalimumab, comment volume increased significantly over time (rho 0.90; P = .04, rho 0.89, P = .01).
UNASSIGNED: Our analysis of a large online community suggests a growing acceptance of biologic therapies among patients with CD over time. These data provide additional insight into the multifaceted framework shaping patients\' perceptions of anti-TNFs.